Skip to main content

Indoleamine 2,3-dioxygenase/IDO Antibody (OTI2B5) - Azide and BSA Free

Novus Biologicals, part of Bio-Techne | Catalog # NBP2-71038

Novus Biologicals, part of Bio-Techne

Key Product Details

Species Reactivity

Human

Applications

Immunocytochemistry/ Immunofluorescence, Immunohistochemistry, Immunohistochemistry-Paraffin, Western Blot

Label

Unconjugated

Antibody Source

Monoclonal Mouse IgG1 Clone # OTI2B5

Format

Azide and BSA Free

Concentration

LYOPH mg/ml

Product Specifications

Immunogen

Full length human recombinant protein of human IDO1(NP_002155) produced in HEK293T cell.

Clonality

Monoclonal

Host

Mouse

Isotype

IgG1

Theoretical MW

45.1 kDa.
Disclaimer note: The observed molecular weight of the protein may vary from the listed predicted molecular weight due to post translational modifications, post translation cleavages, relative charges, and other experimental factors.

Scientific Data Images

Western Blot: Indoleamine 2,3-dioxygenase/IDO Antibody (OTI2B5)Azide and BSA Free [NBP2-71038]

Western Blot: Indoleamine 2,3-dioxygenase/IDO Antibody (OTI2B5)Azide and BSA Free [NBP2-71038]

Western Blot: Indoleamine 2,3-dioxygenase/IDO Antibody (OTI2B5) - Azide and BSA Free [NBP2-71038] - Analysis of HEK293T cells were transfected with the pCMV6-ENTRY control (Left lane) or pCMV6-ENTRY IDO.
Immunocytochemistry/ Immunofluorescence: Indoleamine 2,3-dioxygenase/IDO Antibody (OTI2B5) - Azide and BSA Free [NBP2-71038]

Immunocytochemistry/ Immunofluorescence: Indoleamine 2,3-dioxygenase/IDO Antibody (OTI2B5) - Azide and BSA Free [NBP2-71038]

Immunocytochemistry/Immunofluorescence: Indoleamine 2,3-dioxygenase/IDO Antibody (OTI2B5) - Azide and BSA Free [NBP2-71038] - Analysis of COS7 cells transiently transfected by pCMV6-ENTRY IDO1.
Immunohistochemistry: Indoleamine 2,3-dioxygenase/IDO Antibody (OTI2B5) - Azide and BSA Free [NBP2-71038]

Immunohistochemistry: Indoleamine 2,3-dioxygenase/IDO Antibody (OTI2B5) - Azide and BSA Free [NBP2-71038]

Immunohistochemistry: Indoleamine 2,3-dioxygenase/IDO Antibody (OTI2B5) - Azide and BSA Free [NBP2-71038] - Staining of paraffin-embedded Human lymphoma tissue using anti-IDO1 mouse monoclonal antibody. (Heat-induced epitope retrieval by 10mM citric buffer, pH6.0, 120C for 3min.

Applications

Application
Recommended Usage

Immunocytochemistry/ Immunofluorescence

1:100

Immunohistochemistry

1:150

Western Blot

1:4000
Please Note: Optimal dilutions of this antibody should be experimentally determined.

Formulation, Preparation, and Storage

Purification

Immunogen affinity purified

Reconstitution

we recommend adding 100uL distilled water to a final antibody concentration of about 1 mg/mL. To use this carrier-free antibody for conjugation experiment, we strongly recommend performing another round of desalting process.

Formulation

Lyophilized from PBS (pH 7.3) with 8% Trehalose

Format

Azide and BSA Free

Preservative

No Preservative

Concentration

LYOPH mg/ml

Shipping

The product is shipped with polar packs. Upon receipt, store it immediately at the temperature recommended below.

Stability & Storage

Store at -20C. Avoid freeze-thaw cycles.

Background: Indoleamine 2,3-dioxygenase/IDO

Gamma-interferon (IFNG; MIM 147570) has an antiproliferative effect on many tumor cells and inhibits intracellular pathogens such as Toxoplasma and Chlamydia, at least partly because of the induction of indoleamine 2,3-dioxygenase (INDO; EC 1.13.11.42). This enzyme catalyzes the degradation of the essential amino acid L-tryptophan to N-formylkynurenine.[supplied by OMIM]

Alternate Names

3dioxygenase, IDO, IDO1, INDO, Indoleamine 2

Gene Symbol

IDO1

Additional Indoleamine 2,3-dioxygenase/IDO Products

Product Documents

Certificate of Analysis

To download a Certificate of Analysis, please enter a lot number in the search box below.

Product Specific Notices

This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.

Loading...
Loading...
Loading...
Loading...
Loading...